Details for Patent: 8,858,996
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 8,858,996 protect, and when does it expire?
Patent 8,858,996 protects VIMOVO and is included in one NDA.
This patent has thirty-seven patent family members in twenty-two countries.
Summary for Patent: 8,858,996
| Title: | Pharmaceutical compositions for the coordinated delivery of NSAIDS |
| Abstract: | The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages. |
| Inventor(s): | Plachetka; John R. (Chapel Hill, NC) |
| Assignee: | Pozen Inc. (Chapel Hill, NC) |
| Application Number: | 14/244,471 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,858,996 |
|
Patent Claim Types: see list of patent claims | Composition; Dosage form; Use; |
Drugs Protected by US Patent 8,858,996
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER | See Plans and Pricing | ||
| Horizon | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | AB | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER | See Plans and Pricing | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,858,996
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 474559 | See Plans and Pricing | |||
| Australia | 2002305758 | See Plans and Pricing | |||
| Australia | 2006235929 | See Plans and Pricing | |||
| Australia | 2009200966 | See Plans and Pricing | |||
| Australia | 2009290712 | See Plans and Pricing | |||
| Brazil | PI0918492 | See Plans and Pricing | |||
| Canada | 2449098 | See Plans and Pricing | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
